May. 17 at 4:59 AM
$SLS Frankly, we're starting to read absurd numbers here regarding a potential 15B BO. Only the drug SLS009, approved as a first-line treatment for AML and aggressive lymphomas (DLBCL and PTCL), can achieve a global turnover of 3B. In solid tumors, the ASXL1 mutation in combination with immunotherapies or chemotherapy has a potential turnover of 5B. Obviously, SLS should start a trial as soon as possible with a basket of solid tumors with ASXL1 mutations, given that preclinical results have been excellent. The overall turnover, theoretical for now, of the drug SLS009 is in the order of 8B. What I mean is that the drug alone could be worth 8 x 5 = 40B if SLS manages to successfully complete these two trials, the current one and the one on solid tumors.
